Ad hoc announcement pursuant to Art. 53 LR
Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all
Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, March 14, 2023, 7 am CET β Newron Pharmaceuticals S.p.A. (βNewronβ) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease
Ad hoc announcement pursuant to Art. 53 LR
Statistically significant, clinically meaningful improvements over baseline were seen across efficacy endpoints after six
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
